In The Wall Street Journal, Scott W. Atlas of the Hoover Institution discusses various government policies that are threatening medical innovation. He identifies Obamacare, for example, as a culprit.
A new study by Nicole Craig and Mark Craig, professors of economics at Lafayette University, estimates that the cost of federal regulations is $2 trillion. That amounts to billions of hours in compliance.
POST byRituparna Basu | View All PostsSeptember 12, 2014
Last week I was a guest on The Rick Amato Show. We discussed the latest issues surrounding Obamacare, including newly discovered taxes in the law, whether Obamacare is here to stay and the real solution for solving America’s health care problems.
In Tuesday’s Wall Street Journal, Alex Tabarok reviews a new book that provides yet another glimpse into the inner workings of our destructive regulatory state. The book, called Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances, chronicles the fight by a company called MELA Sciences to win approval from the FDA for a noninvasive method for detecting skin cancer. Initially enthusiastic about the product, the FDA later turned against the company when a new FDA director with a less favorable view of business came on board. The author of the book, who was the company’s CEO at the time (he has since retired), spent a year of his life at great personal cost fighting with the FDA before prevailing.
Despite Obamacare’s rocky rollout and continuing implementation problems, proponents insist that what the law is trying to do is fundamentally good. In this talk, given on June 4 at ARI’s headquarters in southern California, I challenge this claim, making the case that nothing about Obamacare is motivated by good intentions.
Advocates of universal coverage seek to create a society in which, if you can’t afford health insurance, the government forces others to provide it for you. What is the moral defense for treating some people as slaves to the needs of others?
In this episode of The Debt Dialogues, I interview the Cato Institute’s director of health policy studies, Michael Cannon, on Obamacare and its effects on young Americans.
